This Blog is dedicated to reportage and analysis of Civil Commercial Laws and Litigation, including Intellectual Property Laws. Follow @jsaideepak on Twitter for updates. Subscribe to thedemandingmistress@googlegroups.com

I thank a good friend and well-wisher of the blog for sharing this information with me!

Readers may recall that in an earlier
post, I had blogged on dismissal of Cipla’s appeal against the Single Judge’s
order restraining Cipla from marketing its drug, without staying the revocation
of the Sunitinib patent.

Let’s wait for the order of the Supreme Court to
understand the reasons for setting aside the Sunitinib revocation, and for
allowing Cipla to sell its drug.